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ABBREVIATIONS	
aRGc:	apical	radial	glial	cell	
CC:	corpus	callosum	
ERG:	electroretinogram	
EVA:	vestibular	aqueduct	enlargement		
HPE:	holoprosencephaly	
IHA:	interhypothalamic	adhesion		
ID:	intellectual	disability	
IQ:	Intelligence	Quotient		
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IUGR:	intrauterine	growth	retardation	
FSIQ:	full	scale	intellectual	quotient	
MCPH:	autosomal	recessive	primary	microcephaly			
NGS:	next	generation	sequencing	
OSVZ:	subventricular	zone	
PCM:	pericentriolar	material		
PM:	primary	microcephaly	
SD:	standard	deviation	
SD-OCT:	spectral	domain	optical	coherence	tomography	
SNHL:	sensorineural	hearing	loss	
SVZ:	subventricular	zone	
VZ:	ventricular	zone	
WG:	week	of	gestation	
WISC	IV:	Wechsler	Intelligence	Scale	for	Children-IV		
WPPSI	III:	Wechsler	Preschool	and	Primary	Scale	of	Intelligence	
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ABSTRACT	
Background:	 Primary	 hereditary	 microcephaly	 (MCPH)	 comprises	 a	 large	 group	 of	 autosomal	
recessive	disorders	mainly	affecting	cortical	development	and	resulting	in	a	congenital	impairment	of	
brain	growth.	Despite	the	identification	of	more	than	25	causal	genes	so	far,	it	remains	a	challenge	to	
distinguish	between	different	MCPH	forms	at	the	clinical	level.	
Methods:	 7	 patients	with	 newly	 identified	mutations	 in	CDK5RAP2	 (MCPH3)	were	 investigated	 by	
performing	 prospective,	 extensive	 and	 systematic	 clinical,	 MRI,	 psychomotor,	 neurosensory	 and	
cognitive	examinations	under	similar	conditions.	
Results:	All	patients	displayed	neurosensory	defects	in	addition	to	microcephaly.	Small	cochlea	with	
incomplete	partition	type	II	was	found	in	all	cases	and	was	associated	with	progressive	deafness	in	4	
of	 them.	 Furthermore,	 the	 CDK5RAP2	 protein	was	 specifically	 identified	 in	 the	 developing	 cochlea	
from	 human	 fetal	 tissues.	 Microphthalmia	 was	 also	 present	 in	 all	 patients	 along	 with	 retinal	
pigmentation	 changes	 and	 lipofuscin	 deposits.	 Finally,	 hypothalamic	 anomalies	 consisting	 of	
interhypothalamic	adhesions,	a	congenital	midline	defect	usually	associated	with	holoprosencephaly,	
was	detected	in	5	cases.		
Conclusion:	This	is	the	first	report	indicating	that	CDK5RAP2	not	only	governs	brain	size	but	also	plays	
a	role	 in	ocular	and	cochlear	development	and	 is	necessary	 for	hypothalamic	nuclear	separation	at	
the	midline.	Our	data	 indicate	that	CDK5RAP2	should	be	considered	as	a	potential	gene	associated	
with	deafness	and	forme	fruste	of	holoprosencephaly.	These	children	should	be	given	neurosensory	
follow-up	 to	 prevent	 additional	 comorbidities	 and	 allow	 them	 reaching	 their	 full	 educational	
potential.		
	
	 	
5	
	
INTRODUCTION	
Primary	 microcephaly	 (PM)	 is	 a	 rare	 neuro-developmental	 disorder	 characterized	 by	 congenital	
microcephaly,	intellectual	disability	of	variable	severity	(ID)	and	occasional	epilepsy	that	may	reflect	
cortical	mantle	defects	[1–3].		
Clinically,	PM	includes	isolated	PM	(MicroCephaly	Primary	Hereditary	(MCPH),	PM	with	short	stature	
(Seckel	 syndrome,	 microcephalic	 primordial	 dwarfism),	 and	 syndromic	 PM	 (associated	 with	 non-
neurodevelopmental	manifestations).	MCPH	and	Seckel	syndrome	may	be	further	subdivided	by	the	
presence	 of	 cortical	 malformations	 and/or	 chorioretinopathy.	 Although	 this	 classification	 helps	
managing	the	differential	diagnosis	of	the	patients,	it	does	not	reflect	underlying	mechanisms.	Most	
PMs	 show	autosomal	 recessive	 inheritance	 (for	 review,	 see	 [1,	 3]),	 although	dominant	 forms	have	
occasionally	been	described	[4–6]	and	a	mitochondrial	origin	has	been	proposed	[7].	To	date,	more	
than	100	genes	have	been	implicated	in	PM	(for	review,	see	[8]).	
The	 cyclin-dependent	 kinase	 5	 (CDK5)	 regulatory	 subunit	 associated	 protein-encoding	 gene	
(CDK5RAP2;	 OMIM	 608201)	 is	 among	 the	 first	 genes	 initially	 identified	 in	 PM	 (MCPH3,	 OMIM	
604804)	 [9].	 CDK5RAP2	 regulates	 CDK5	 activity,	 required	 for	 centrosome	 cohesion	 [10],	 centriole	
duplication	 and	 attachment	 of	 the	 centrosome	 to	 the	 spindle	 pole	 [11],	 and	 plays	 a	 role	 in	
microtubule	plus-end	dynamics	[12].	In	addition,	it	is	essential	for	DNA	damage	response	[13].	In	the	
developing	mouse	neocortex,	 Cdk5rap2	 is	 crucial	 for	 the	maintenance	of	 apical	 neural	 progenitors	
[14,	15]	as	its	deficiency	leads	to	spindle	orientation	defects,	premature	cell	cycle	exit	and	increased	
cell	 death	 during	 neurogenesis,	 resulting	 in	 a	 reduction	 in	 the	 final	 neuron	 number	 [15].	 During	
human	neurogenesis,	CDK5RAP2	 is	widely	expressed	 in	 the	ventricular	and	 subventricular	 zones	at	
week	of	gestation	WG12,	WG18,	and	in	the	superficial	layers	of	the	neocortex	until	term	[16].		
Variants	in	CDK5RAP2	were	first	identified	in	association	with	PM	in	2005	[9].	Since	then,	35	patients	
from	17	families	have	been	described,	essentially	through	single	case	or	mutation	reports,	and	with	
limited	clinical	details	[9,	17–29].	Most	mutations	reported	are	nonsense	or	frameshift	variants	(i.e.	
null	variants),	except	for	three	siblings	carrying	missense	variants	[22]	(Figure	1	and	Supplementary	
Table	1).	Patients	with	pathogenic	variants	in	CDK5RAP2	display	heterogeneous	phenotypes:	the	first	
11	 patients	 reported	 are	 microcephalic	 individuals	 (OFC	 from	 -4	 to	 -9	 SD	 during	 childhood)	 with	
normal	stature	and	mild-to-moderate	ID	[9,	18,	26].	Three	infants	were	reported	with	PM	and	mildly	
short	stature	(from	-2.5	to	-4	SD)	that	corrected	with	age.	Three	additional	patients	from	2	pedigrees	
were	reported	with	Seckel-like	microcephalic	dwarfism	[29].	Feeding	difficulties	[9,	20,	24,	26],	skin	
areas	of	hypo-	[9]	and/or	hyperpigmentation	[21,	29],	seizures	[9]	and	deafness	[9,	21,	26,	29]	have	
been	 reported.	 CDK5RAP2	 variants	 have	 also	 been	 reported	 in	 patients	 with	 corpus	 callosum	
agenesis	without	microcephaly	 [22].	One	patient	developed	acute	 lymphoblastic	 leukemia	 [9].	 This	
heterogeneity	 is	 not	 supported	 by	 any	 genotype/phenotype	 correlation	 and	 the	 possibility	 of	
additional	recessive	or	de	novo	mutation	has	not	been	ruled	out.	
Despite	 this	 range	 of	 presentations,	 MRI	 data	 are	 lacking.	 Brain	 MRIs	 performed	 in	 CDK5RAP2	
patients	 have	 failed	 to	 provide	 specific	 information.	When	 available,	 data	 only	 indicate	 a	 reduced	
brain	 size	 and	 a	 qualitative	 impression	of	 gyral	 simplification	 [23,	 26,	 28,	 29],	 similar	 to	 reports	 in	
other	MCPH	 [30].	Hypoplasia,	 agenesis	or	dysplasia	of	 the	 corpus	 callosum	have	been	occasionally	
reported	[21,	22,	24].	As	MRI	data	have	not	been	reported	for	the	majority	of	patients,	the	possibility	
that	CDK5RAP2	patients	have	specific	brain	malformations	cannot	be	ruled	out.		
6	
	
Furthermore,	no	systematic	neuropsychological	assessment	of	the	patients	has	been	published.	Mild	
to	moderate	ID	was	reported	in	the	first	cases	[9,	20,	31].	However,	this	finding	has	been	challenged	
by	 more	 recent	 studies	 using	 neuropsychological	 assessments	 [26,	 28]	 surprisingly	 showing	 that	
individuals	 with	 CDK5RAP2	 variants	 have	 a	 normal/borderline	 IQ.	 Hence,	 the	 severe	 reduction	 in	
brain	 volume	 in	 patients	 with	 CDK5RAP2	 variants	 does	 not	 appear	 to	 result	 in	 an	 equally	 severe	
impact	on	cognitive	functions.	There	is	thus	an	urgent	need	for	reliable	data	on	cognitive	prognosis	in	
MCPH	as	a	prerequisite	for	genetic	counseling,	adequate	educational	therapy	and	medical	follow-up.	
Here,	we	took	advantage	of	a	cohort	of	7	new	CDK5RAP2	patients,	the	largest	series	reported	so	far,	
to	 revisit	 the	 phenotype	 associated	 with	 CDK5RAP2	 by	 performing	 prospective,	 extensive	 and	
systematic	 clinical,	 MRI,	 psychomotor,	 neurosensory	 and	 cognitive	 examinations	 under	 similar	
conditions.	We	report	4	novel	and	4	very	recently	described	CDK5RAP2	mutations	[7]	and	show	that,	
in	 addition	 to	PM,	 all	 patients	have	 skin	pigmentation	 changes	 as	well	 as	 congenital	 neurosensory	
defects,	 including	 microphthalmia	 and	 retinal	 pigmentation	 defects,	 and	 a	 unique	 cochlear	
malformation.	 In	 agreement	 with	 this	 latter	 finding,	 immuno-labeling	 on	 human	 fetal	 tissues	
identifies	the	CDK5RAP2	protein	in	the	developing	cochlea,	in	addition	to	the	fetal	brain.	Moreover,	5	
patients	exhibit	a	hypothalamic	anomaly.	Our	data	indicate	that	the	CDK5RAP2-related	phenotype	is	
wider	 but	 more	 homogeneous	 than	 previously	 thought,	 and	 that	 ophthalmic	 and	 auditory	
investigations	should	be	systematically	included	in	the	clinical	follow-up	of	these	children.	
	
MATERIAL	and	METHODS	
1. Next	Generation	Sequencing	or	Targeted	sequencing		
Homozygosity	mapping	(patients	1	&	2)	was	performed	by	SNP	array	analysis	(SurePrint	G3	Human	
Genome	 CGH	 +	 SNP	 Microarray	 kit,	 Agilent	 Technologies).	 Coding	 exons	 and	 splice	 junctions	 of	
CDK5RAP2	were	sequenced	by	standard	bidirectional	Sanger	methods.	Mutations	 in	patients	3	to	5	
were	identified	by	targeted	Next	Generation	Sequencing.	CDK5RAP2	was	included	on	a	microcephaly	
gene	 panel	 for	 screening	 by	 multiplex	 PCR	 enrichment	 on	 a	 microfluidic	 support	 (Access-Array,	
Fluidigm	 Corporation)	 and	 2×150bp	 sequencing	 with	 an	 Illumina	MiSeq	 system.	 Sequencing	 reads	
were	 mapped	 to	 the	 UCSC	 Genome	 Browser	 (hg19)	 with	 MiSeq	 software,	 the	 Burrows-Wheeler	
Aligner,	and	the	Genome	Analysis	Toolkit,	and	panel	exons	were	99%	covered.	Variants	were	filtered	
against	MAF	(>0.005),	dbSNP,	1000	Genomes,	the	NHLBI	ESP	Exome	Variant	Server,	and	an	in-house	
dataset.	Rare	variants	were	annotated	 for	 functional	 features	of	 coding	nucleotides	with	publically	
available	 databases,	 Polyphen2,	 SIFT,	Mutation	 taster	 and	 Align	 GVGD.	 Confirmation	 of	mutations	
identified	by	NGS	and	their	familial	segregation	were	carried	out	(Sanger	sequencing).	Patients	6	and	
7	 were	 part	 of	 a	 whole-exome	 sequencing	 study	 in	 a	 larger	 microcephaly	 cohort.	 Methods,	
sequencing	results	and	few	clinical	hallmarks	of	these	two	patients	were	reported	elsewhere	[7].	
	
2. Clinical,	neuroimaging	and	neurosensory	assessment	of	the	patients	
Seven	 patients	 carrying	CDK5RAP2	 variants	 identified	 in	 Paris	 or	 Zurich	 genetic	 departments	were	
recruited	between	2014	and	2018.	Inclusion	criteria	were:	OFC	≤	-2	SD	at	birth	(WHO	growth	charts	
(www.who.int/childgrowth/standards)),	no	environmental	 cause	of	PM.	Parents	provided	 informed	
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consent	for	children’s	participation	in	a	protocol	approved	by	the	ethics	committee	of	Paris	and	was	
registered	at	ClinicalTrials.gov,	Identifier:NCT01565005.		
The	 protocol	 included	 a	 detailed	 clinical	 and	 neurological	 examination	 and	 the	 following	
exams/assessments:		
Cerebral	MRI,	 included	 coronal	 T2-weighted	 and	 T1-weighted	 3D	 sequences	with	millimeter	 slices	
(1.5	Tesla	Philips	scanner).	
Cognitive	 assessment:	 Intellectual	 abilities	 were	 assessed	 using	 the	 international	Wechsler	 scales,	
according	to	age	(WISC	IV:	6	to	16	years,	n=5,	patients	1,	4-7;	WPPSI	III:	3	to	7	years	7	months,	n=2,	
patients	 2	 and	 3).	 Full	 Scale	 IQ	 (FSIQ)	 was	 calculated	 from	 four	 scores	 for	 WISC	 IV:	 a	 Verbal	
Comprehension	Index	(VCI),	a	Perceptual	Organization	Index	(POI),	a	Working	Memory	Index	(WMI)	
and	 a	 Processing	 Speed	 Index	 (PSI).	 The	 scores	 are	 independent	 and	 involve	 specific	 cognitive	
abilities	such	as	lexical	stock,	general	knowledge,	verbal	comprehension	and	verbal	reasoning	(VCI);	
visuomotor	and	visuospatial	skills	to	examine	a	problem,	organize	thoughts	and	find	solutions	using	
cubes/pictures	 (POI);	 short-term	 memory,	 concentration	 abilities,	 mental	 manipulation,	 planning	
abilities,	 cognitive	 flexibility,	 arithmetic	 reasoning	 (WMI),	 performance	 speed	 in	 graphic	 realization	
and	 visual	 discrimination	 (PSI).	 FISQ	 was	 calculated	 from	 three	 scores	 for	 WPPSI	 III	 (verbal	 IQ,	
performance	IQ,	and	processing	speed	quotient).	Only	the	non-verbal	reasoning	scale	(POI)	has	been	
calculated	for	patient	3	due	to	language	barrier.		
Neurosensory	assessment		
Ophthalmological	 assessment	 included	 visual	 acuity	 measurement	 with	 Snellen	 optotypes	 axial	
length	 measurement,	 bio-microscopy	 of	 the	 anterior	 segment	 and	 ocular	 fundus	 examination.	
Fundus	 auto-fluorescence	 imaging,	 full	 field	 scotopic	 and	 photopic	 electroretinograms	 (ERGs),	 a	
pattern-ERG	 (pERG)	 and	 electro-oculography	 (EOG)	 were	 performed	 in	 all	 patients.	 Two	 patients	
underwent	optical	coherence	tomography	(3D-OCT).		
Audiological	assessment	included	pure	tone	and	speech	audiometry.		
Temporal	bone	high-resolution	CT	included	helical	acquisition	of	submillimeter	slices	with	multiplanar	
reconstructions	(Philips	Brilliance	64-CT).		
3. Statistical	analysis	
The	 four	 scores	 required	 to	 calculate	 the	 FSIQ	 were	 compared	 to	 search	 for	 specific	 learning	
disorders	(one-way	ANOVA	and	Bonferroni	post-hoc	test).	p<0.05	indicated	significance.	
4. Immunohistology	in	human	foetal	cochlea	and	brain	
Human	fetal	temporal	bone	(1)	and	brains	(2)	specimen	were	obtained	from	morphologically	normal	
miscarried	fetuses	(WG12	for	(1),	WG8	and	WG12	for	(2)),	with	the	informed	written	consent	of	the	
parents	 in	accordance	with	French	 law.	Specimen	were	fixed,	paraffin-embedded	and	processed	to	
obtain	 7-8	 µm	 sections.	 Immunohistochemistry	 was	 performed	 using	 antibodies	 against	 γ-Tubulin	
(ab11316,	Abcam),	Myosin	VI	(M0691,	Sigma),	CDK5RAP2	(A300-554A,	Bethyl).	Images	were	acquired	
using	an	Confocal	Leica	SP8.		
	
RESULTS	
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1. Molecular	findings		
All	CDK5RAP2	mutations		are	depicted	in	Figure	1,	Table	1	and	Supplementary	Table	1.		
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Table 1 
 
Family 1 1 2 4 4 5 6 
Subject patient 1  patient 2  patient 3  patient 4  patient 5  patient 6 patient 7 
Gender M F F F M M F 
CDK5RAP2 
variant 
c.564_565dup 
(p.Lys189Argfs*15) 
c.564_565dup 
(p.Lys189Argfs*15
) 
c.5495dup, 
(p.Leu1832Phefs*3) 
; 
c.217-220del, 
(p.Glu73Thrfs*4) 
c.1303dup 
(p.Thr435Asnfs*4) 
c.1303dup 
(p.Thr435Asnfs*4) 
c.558_559
del, 
(p.Glu186
Aspfs*32) 
; 
c.4441C>T
, 
(p.Arg148
1*) 
c. 
3928G>T, 
(p.Glu1310
*) 
;  
c.4546G>T, 
(p.Glu1516
*) 
Ethnic origin Tunisia Tunisia Serbia Morocco Morocco Italian / 
Romanian 
Swiss/ 
Austrian 
Consanguinity yes yes yes yes yes no no 
mother HC (cm, 
SD) 
56 (+1) 56 (+1) 54.5 (0) Not available Not available 53 cm  Not 
available 
father HC (cm, 
SD) 
60 (+3.5) 60 (+3.5) 57.5 (+1.5) Not available Not available 58.5 cm Not 
available 
pregnancy 
duration (weeks 
of amaenorrhea) 
38 40 39   39 38 41 39 
prenatally 
diagnosed 
microcephaly 
(ultrasounds) 
3rd trimester 2nd trimester non reported 
microcephaly 
non reported 
microcephaly 
3rd trimester 2nd 
trimester 
3rd 
trimester 
fetal cranial MRI Not performed Not performed Not performed Not performed Not performed Not 
available 
Not 
performed 
Weight at birth 
(kg, SD) 
2.490 (-2) 3.160 (-0.5) 2.965 (-1) 2.260 (-2,5) 1.520 (-3,5) 2.900 (-
1,5) 
2.005 (-3) 
Length at birth 
(cm, SD) 
45 (-3.5) 45 (-3) 47 (-2,5) 45 (-3) 41 (-5,5) 46 (-3) 44 (-3) 
HC at birth (SD)  31 (-2,2) 30.5 (-2.5) 30.5 (-2,5) 29.5 (-3) 26.5 (-5) 30.5 (-2,5) 28 (-4) 
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age at last 
examination 
(years) 
10 4.5 4.5 11 10 8 14,5 
Weight at last 
examination 
(kg, SD) 
52.5 (+5,5) 12,5 (-2) 19.5 (+2) 48.3 (+3) 21.5 (-2) 26 (+0,5) 34,3 (-3) 
length at last 
examination (m, 
SD) 
1.34 (0) 0.94 (-2) 1.07 (+1) 1.44 (+0,5) 1.27 (-1.5) 118 (-1,5) 146,4 (-2) 
HC at last 
examination 
(cm, SD) 
48.5 (-3,4) 42 (-6,6) 42.5 (-6,2) 47.5 (-4) 42 (-7,7) 42.8 cm (-
7,2) 
43.2 (-7.3) 
        
        
Development              
age of walking 
(months) 
10.5 16 14 11 18 12 18 
mastication (if 
delayed, age in 
months) 
Delayed (24) Delayed (24) Normal Normal Delayed (24) Delayed 
(30-36) 
Normal 
age of first 
comprehensive 
words (months) 
18 18 30 24 54 18 21 
age of first 
sentences 
(years) 
4.5 2 4.5 3 unvested, severe 
articulation 
disorders 
8 3.5 
Language 
articulation 
(normal, 
delayed) 
Normal Normal Delayed Normal Delayed Delayed 
(30 mo) 
Delayed 
Social 
interaction 
(normal/delayed
) 
Normal Normal Normal Normal Normal Normal Normal 
Years in kinder 
garden 
3y 0 1y     
Elementary 
school 
first year in normal 
class, then home 
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schooling 
        
        
Seizures 0 0 0 0 0 0 0 
        
Neurological 
Findings 
             
Hypertonia 
within the first 
two years of life 
0 0 0 0 0 yes yes 
Hypotonia within 
the first two 
years of life 
0 0 0 0 0 no axial 
hypotonia 
pyramidal 
syndrome 
0 0 0 0 0 no 0 
inferior limb 
spasticity 
0 0 0 0 0 yes Yes 
Ataxia 0 0 0 0 0 uncoordina
ted 
movement
s 
Yes 
        
Behaviour              
hyperactivity yes yes yes before 7-8 years 
old  
before 7-8 years 
old  
Quiet 
behaviour, 
but 
hyperactivi
ty 
episodes 
no 
Tic disorders no no no no 0  (but 
repetitive 
movement
s) 
no 
agressiveness no no no no 0 episodes of 
aggressive
ness  
no 
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Intellectual 
abilities 
             
total IQ 62 67  40 56 52 46 
        
sensorineural 
anomalies 
             
congenital 
hearing loss 
(uni/bilateral) 
no no no no no 0 no 
progressive 
hearing loss 
(uni/bilateral), 
age 
bilateral, 9y no Unilateral, 7y no bilateral, 7y Bilateral, 
10 y 
no 
hearing 
(auditory 
threshold) 
Right: severe 
deafness (70-80 dB) 
Left: moderate 
deafness (20-50 dB) 
normal Oto-acoustic	
emissions	 within 
the first months of 
life 
Right : severe 
deafness (70dB), 
Left : normal 
Right: normal (15-
20 dB), Left: 
normal (15-25 dB) 
Right: severe 
deafness (80-90 
dB), Left: severe 
deafness (60-70 
dB) 
Right: 
severe 
deafness 
(60-80 dB)               
Left: 
moderate 
to severe 
deafness 
(40-60/60-
80 dB) 
Right and 
left : 
normal 
hearing aid 
(uni/bilateral) 
unilateral no unilateral no bilateral bilateral no 
        
retinal 
hypopigmentatio
n (uni/bilateral) 
bilateral  bilateral bilateral bilateral  bilateral ? yes 
retinal 
hyperpigmentati
on 
(uni/bilateral) 
bilateral  bilateral bilateral bilateral  bilateral ? no 
ERG normal normal normal normal normal Not done normal 
        
skin anomalies              
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area of 
hypopigmentatio
n  
yes yes yes no no no yes  
area of 
hyperpigmentati
on  
yes yes no yes yes yes 
(Several 
café-au-
lait spots 
on trunk, 
arms and 
legs) 
yes  
CC:	corpus	callosum,	dB:	decibel,	ERG:	electroretinogramm,	IQ:	intellectual	quotient,	HC:	head	circumference,	SD:	standard	deviation.	
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Homozygosity	 mapping	 performed	 by	 SNP	 array	 analysis	 revealed	 a	 common	 homozygous	 locus	
including	CDK5RAP2	in	patients	1	and	2	and	subsequent	Sanger	sequencing	of	CDK5RAP2	revealed	a	
homozygous	 frameshift	 duplication	 of	 2bp	 in	 exon	 7,	 leading	 to	 a	 premature	 stop	 codon	
(c.564_565dup,	 [p.(Lys189Argfs*15)]	 [GenBank:	 NM_018249.5]	
Chr9(GRCh37):g.123,298,747_123,298,748dup).	 Both	 parents	 were	 heterozygous	 carriers.	 Gene	
panel	analysis	was	performed	in	patients	3	to	5.	Patient	3	was	found	to	carry	“assumed	compound-
heterozygous”	CDK5RAP2	variants,	as	the	parents	were	not	available	for	testing:	one	4bp	deletion	in	
exon	 4	 (c.217_220del,	 [p.(Glu73Thrfs*4)]	 [GenBank:NM_018249.5];	
Chr9(GRCh37):g.123313156_123313159del)	 and	 a	 1bp	 duplication	 in	 exon	 36	 (c.5495dup,	
[p.(Leu1832Phefs*3)]	 [GenBank:NM_018249.5];	 Chr9(GRCh37):g.123156873dup).	 These	 2	 variants	
are	predicted	to	induce	a	frameshift	leading	to	null	alleles.	Patients	4	and	5	displayed	a	homozygous	
pathogenic	mutation	in	exon	12.	This	single	nucleotide	duplication	creates	a	premature	stop	codon	4	
codons	 downstream	 (c.1303dup,	 [p.(Thr435Asnfs*4)]	 [GenBank:	 NM_018249.5];	
Chr9(GRCh37):g.123280713dup)	 predicting	 a	 null	 allele.	 The	 father	 was	 heterozygous	 carrier	 (no	
sample	available	from	the	mother).		
	
None	of	 the	mutations	 found	 in	 patients	 1	 to	 3	 are	 present	 in	 public	 databases	 (gnomAD,	 dbSNP,	
1000	 Genomes,	 the	 NHLBI	 Exome	 Variant	 Server	 (EVS)	 and	 the	 Exome	 Aggregation	 Consortium	
(ExAC)	browser).	The	variant	identified	in	patients	4	and	5	has	been	reported	only	once,	in	the	Latino	
population	of	the	gnomAD	database,	and	has	never	been	reported	in	the	homozygous	state.	
Patients	 6	 and	 7	were	 found	 to	 be	 compound	heterozygous	 for	 truncating	 variants	 by	 trio	whole-
exome	 sequencing	 as	 recently	 described	 [7].	 Each	patient	 carried	one	unreported	 variant	 and	one	
with	a	very	low	minor	allele	frequency,	both	heterozygous,	in	the	ExAC/gnomAD	databases.	Patient	6	
harbored	 NM_018249.5(CDK5RAP2):c.[558_559delGA]+[c.4441C>T],	
p.[(Glu186Aspfs*32)]+[(Arg1481*)],	 Chr9(GRCh37):g.[123298753_123298754del];[123171568C>T]	
with	 the	 mother	 heterozygously	 carrying	 c.[558_559delGA]+[=],	 p.[(Glu186Aspfs*32)]+[=]	
(unreported)	 and	 the	 father	 heterozygously	 carrying	 c.[c.4441C>T]+[=],	 p.[(Arg1481*)]+[=]	
(rs587783390;	 ExAC:	 A=0.00005660	 /4,	 no	 homozygotes).	 Patient	 7	 harbored	
NM_018249.5(CDK5RAP2):c.[3928G>T];[4546G>T]	 p.[(Glu1310*)];[(Glu1516*)]	
Chr9(GRCh37):g.[123199600C>A];[123171463C>A]	 with	 the	 mother	 heterozygously	 carrying	
c.[4546G>T];[=]	 p.[(Glu1516*)];[(=)]	 (rs374351172;	 ExAC:	 A=0.00002472/3,	 no	 homozygotes,	
gnomAD:	A=0.00002844/7,	no	homozygotes)	and	the	father	heterozygously	carrying	c.[3928G>T];[=]	
p.[(Glu1310*)];[(=)]	(unreported).	
2. Clinical	characteristics		
Clinical	details	are	summarized	in	Table	1.	Microcephaly	was	confirmed	at	birth	in	all	cases	and	was	
even	detectable	during	the	2nd	or	3rd	trimester	of	pregnancy	in	5/7	patients	before	reaching	a	mean	
OFC	of	-6	+/-	1.7	SD	during	infancy.	Nevertheless,	an	unusual	improvement	of	the	OFC	after	age	2	for	
patients	 1,	 2	 and	 4	 was	 noted	 (Supplementary	 Figure	 1).	 None	 of	 the	 patients	 had	 short	 stature	
beyond	 age	 5.	 Areas	 of	 hypo-	 or	 hyperpigmentation	 of	 the	 skin	 were	 systematically	 found	 in	 all	
patients.	Motor	development	was	also	normal.	 Suspected	around	age	3	because	of	 speech	delays,	
the	 main	 functional	 consequence	 of	 brain	 volume	 reduction	 and	 simplified	 gyri,	 both	 obvious	 on	
brain	MRI	(Supplementary	Figure	2),	was	ID,	ranging	from	mild	to	moderate	(Full	Scale	IQ	[FSIQ]	from	
40	[patient	5]	to	67	[patient	1],	see	Supplementary	Figure	3).	We	cannot	exclude	the	possibility	that	
patient	5,	with	moderate	ID	may	have	a	second	hit	related	to	the	context	of	consanguinity.	However,	
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in	all	patients,	a	relative	preservation	of	verbal	comprehension	(VCI	78	and	75	for	patients	1	and	2)	
and	 visuospatial	 abilities	 (71	 and	 75	 for	 patients	 2,	 3	 and	 6)	 as	 well	 as	 a	 preservation	 of	 mental	
manipulation	was	detected	(78	and	73	for	patients	1	and	4).	None	of	the	patients	exhibited	epilepsy.		
3. 	Developmental	hypothalamic	defect	
Patients	 1,	 2,	 4,	 5	 and	 7	 displayed	 interhypothalamic	 adhesion	 (IHA),	 a	 grey	 matter	 band	 that	
connects	the	dorsomedial	and	ventromedial	hypothalamic	nuclei	and/or	arcuate,	paraventricular	or	
preoptic	nuclei	on	both	sides	of	the	third	ventricle	[36,	37]	(Figure	2).	IHA	differs	from	hamartoma	as	
it	 doesn’t	 extend	 into	 the	 third	 ventricle.	 For	 patient	 6,	 brain	 MRI	 was	 performed	 with	 another	
protocol	 including	a	series	of	5mm	slices	without	T1-weighted	3D	sequence,	which	did	not	allow	to	
formally	identify	IHA.	IHA	was	already	noticed	on	the	brain	MRI	performed	at	1	year	of	age	in	patient	
1,	 and	 was	 not	 enhanced	 after	 gadolinium	 injection,	 as	 classically	 described	 for	 glioma,	 another	
differential	diagnosis	of	IHA.	Taken	together,	these	observations	suggest	that	IHA,	which	is	present	at	
least	 in	5/7	patients,	may	be	 caused	by	a	 failure	of	 the	 separation	of	hypothalamic	nuclei	 at	 early	
developmental	stages.		
4. Neurosensory	impairment	(Tables	1-2,	Figures	3-4)		
Retinal	pigmentation	defects:		
Ophthalmological	assessment	showed	normal	bio-microscopy	and	no	oculomotor	disorder.	The	axial	
length	was	below	the	normal	range	in	all	patients	(average:	20.9,	from	20.3	to	22.3	mm;	normal	age	
for	age	>	3	years	old:	23.5	mm).	
In	 all	 patients,	 examination	of	 the	ocular	 fundus	 revealed	 round	or	oval	 regions	of	 focal	 hyper-	 or	
hypopigmentation	 scattered	 in	 the	 periphery	 and	 all	 along	 the	 vascular	 arcade.	 Hyperpigmented	
lesions	consisted	of	either	extended	dark	grey	lesions	or	small	dark	lesions	scattered	in	the	macular	
zone	and	in	the	retinal	periphery	(Figure	3A-B).	Small	round	spots	of	hypopigmentation	were	either	
located	 in	 the	macula	 (Figure	 3B)	 or	 scattered	 in	 the	 periphery	 (Figure	 3A-B).	 All	 hyperpigmented	
lesions	 were	 hypo-autofluorescent	 (Figure	 3C-D),	 while	 hypopigmented	 spots	 were	 hyper-
autofluorescent	(Figure	3C-D).	OCT	was	performed	and	found	normal	in	patients	1	and	4.		
All	patients	being	hyperopic,	best-corrected	visual	acuity	was	20/20	except	 in	 the	youngest	patient	
(patient	 3),	 aged	 4	 and	 non-cooperative,	 whose	 visual	 acuity	 was	 superior	 to	 20/40	 in	 each	 eye.	
Scotopic	and	photopic	flash	ERGs	as	well	as	the	EOG	and	pERG	were	similar	to	age-matched	controls	
(data	not	shown).	
Progressive	hearing	loss	associated	with	congenital	inner	ear	malformation:		
Patients	1,	3,	5	and	6	developed	progressive	uni-	or	bilateral	hearing	loss,	respectively	diagnosed	at	
age	9,	6,	7	and	10	(Table	1).	Audiometric	evaluations	at	diagnosis	showed	severe	hearing	loss	from	70	
to	80	Hz	in	at	least	one	ear	for	all	four	patients.	Patient	1	had	a	unilateral	scotoma	of	the	left	ear	at	
6000	Hz	 at	 60dB,	 and	 a	 77.5	 dB	 threshold	 in	 the	 right	 ear	 (Figure	 4	B-C).	 Close	 to	 normal	 hearing	
levels	 were	 restored	 with	 conventional	 hearing	 aids.	 However,	 patient	 5	 did	 not	 receive	 early	
intervention/rehabilitation.	This	delayed	medical	support	is	likely	to	have	increased	the	receptive	and	
expressive	speech	impairment	caused	by	PM	itself	and	worsened	ID.	Surprisingly,	although	they	had	
been	 stable	 for	at	 least	4	years,	patient	1	has	 recently	undergone	an	 improvement	of	his	auditory	
thresholds,	 which	 is	 now	 at	 42dB	 in	 the	 right	 ear	 and	 26dB	 in	 the	 left	 ear	 on	 average,	 with	 a	
concordant	vocal	threshold.		
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As	sensorineural	hearing	 loss	 (SNHL)	 is	very	unusual	 in	patients	with	PM,	a	 temporal	bone	CT	scan	
was	performed	for	all	patients	except	patient	6	(parental	rejection),	and	revealed	the	same	cochlear	
malformation	in	each	case:	small	cochlea	compared	to	normal	values	on	CT	[32]	and	an	absence	of	
the	interscalar	septa	at	the	apical	turn	(Figure	4A	and	Table	2),	i.e.	compatible	with	the	diagnosis	of	
incomplete	partition	type	II	of	the	Sennaroglu	classification	[33].	 In	addition,	patient	2	displayed	an	
enlarged	vestibular	aqueduct	associated	with	this	cochlear	dysplasia.	In	all	patients,	the	diameter	of	
the	bony	cochlear	nerve	canal	was	reduced	(<1.7	mm),	in	favor	of	a	cochlear	nerve	hypoplasia	[32].		
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Table	2	
	
Neuroradiological 
findings 
Patient 1 
 10 y 
Patient 2 
4.5 y 
Patient 3 
4.5 y 
Patient 4 
11.5 y 
Patient 5 
10 y 
Patient 6  
5 y 
Patient 7 
13.75 y 
Corpus  callosum Raw  /  
3rd 
percentile 
Raw  /  
3rd 
percentile 
Raw  /  
3rd 
percentile 
Raw  /  
3rd 
percentile 
Raw  /  
3rd 
percentile 
Raw  /  
3rd 
percentile 
Raw  /  
3rd 
percentile 
 
APD (mm) 45.7 (59.1) 47.91 (55.5) 42.43 (55.5) 55.86 (59.7) 49.06 (59.1) 30.09 (56.2) 29.39 (61.7) 
FOD (mm) 121.6 (148.6) 113.2 (140.5) 113 (140.5) 130.1 (145) 114.5 (148.6) 113 (142.3) 125 (147.5) 
APD/FOD 0.37 (0.37) 0.42 (0.36) 0.37 (0.36) 0.42 (0.37) 0.42 (0.37) 0.27 (0.36) 0.23 (0.38) 
GT (mm) 9.48 (7.3) 7.25 (6.7) 7.36 (6.7) 8.72 (7.4) 7.96 (7.3) 6.2 (6.9) 7.22 (7.6) 
BT (mm) 7.42 (4) 5.39 (3.5) 6.93 (3.5) 5.46 (4) 6.42 (4) 7.8 (3.7) 5.23 (3.9) 
IT (mm) 7.3 (2.4) 4.82 (1.9) 6.02 (1.9) 6.14 (2.4) 6.32 (2.4) 6 (2) 4.6 (2.5) 
ST (mm) 9.09 (7.7) 10.02 (6.7) 8.11 (6.7) 11.17 (7.7) 10.13 (7.7) 3.9 (6.9) 0 (7.1) 
Gyration simplified simplified simplified simplified simplified simplified simplified 
 
Interhypothalamic  
adhesions 
yes yes no yes yes 
?  
Midline sagittal sections 
> 5 mm 
yes 
Internal ear 
type II incomplete 
partition of the 
cochlea 
type II incomplete 
partition of the cochlea 
Enlarged right 
vestibular aqueduct 
type II incomplete 
partition of the cochlea 
 
type II incomplete 
partition of the cochlea 
 
type II incomplete 
partition of the cochlea 
Not performed 
type II incomplete 
partition of the cochlea 
	
APD:	anteroposterior	diameter	of	the	corpus	callosum,	FOD	_	fronto-occipital	diameter,	GT	_	genu	thickness,	BT:	body	thickness,	IT:	isthmus	thickness,	ST:	splenium	
thickness	(according	to	Garel	et	al.	AJNR,	2011).	
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CDK5RAP2	detection	in	the	fetal	cochlear	epithelium	
The	CDK5RAP2	protein	is	known	to	be	expressed	in	the	VZ	of	both	mouse	and	human	telencephalon	
throughout	neurogenesis	[16].	However,	 its	presence	in	the	inner	ear	has	not	been	documented	so	
far.	Using	immunohistochemistry	for	CDK5RAP2	on	human	fetal	tissues,	we	found	that	it	is	expressed	
in	the	developing	cochlea	in	addition	to	the	fetal	brain.	Co-labeling	of	CDK5RAP2	with	γ-TUBULIN	on	
human	fetal	brain	sections	at	early	(WG8)	and	mild	(WG12)	stages	confirmed	that	CDK5RAP2	is	highly	
expressed	at	the	centrosome	of	the	apical	radial	glial	cells	(aRGCs)	in	the	VZ	(Supplementary	Figure	
4).	 Immunolabeling	 on	 human	 fetal	 cochlea	 at	 WG12,	 showed	 that	 CDK5RAP2	 is	 expressed	 in	
MYOSIN	VI	 (a	protein	expressed	 in	 the	cytoplasm	of	outer	hair	 cells	of	 the	organ	of	Corti)	positive	
cells	(Figure	4	F).	At	the	apical	pole	of	these	outer	hair	cells,	CDK5RAP2	was	also	co-expressed	with	γ-
TUBULIN	 (Figure	 4	 G)	 at	 the	 centrosome,	 concordant	 with	 its	 expression	 within	 the	 VZ.	 Thus	
CDK5RAP2	is	expressed	early	at	the	centrosome	in	the	sensory	epithelium	of	the	organ	of	Corti	as	in	
the	neuroepithelium.		
	
DISCUSSION	
In	 this	 study,	we	 identify	 neurosensory	 impairments	 associated	with	 the	 CDK5RAP2	microcephaly,	
including	 retinal	 pigmentation	 defects	 and	 a	 specific	 cochlear	 malformation	 responsible	 for	
progressive	 sensorineural	 hearing	 loss.	 All	 patients	 examined	 with	 our	 protocol	 displayed	 IHA,	
suggesting	 a	 failure	 in	 hypothalamic	 nuclei	 separation.	 CDK5RAP2	 is	 thus	 crucial	 for	 neurosensory	
development	in	addition	to	brain	development.	
CDK5RAP2	and	brain	development	
In	 agreement	 with	 the	 congenital	 defects	 observed,	 CDK5RAP2	 is	 highly	 expressed	 during	
neurocorticogenesis.	Although	the	protein	has	been	detected	from	WG18	onward	[16],	we	find	that	
CDK5RAP2	 is	 present	 as	 early	 as	WG8	 in	 the	 VZ	 of	 the	 human	 fetal	 cortex,	 at	 the	 centrosome	 of	
aRGCs.	 This	 highlights	 CDK5RAP2	 requirement	 for	 early	 progenitors’	 division	 and	may	 explain	why	
microcephaly	is	often	detected	antenatally.	Similarly,	aRGCs	switch	from	symmetric	(proliferative)	to	
asymmetric	(neurogenic)	division	in	Cdk5rap2-deficient	mice,	which	results	premature	cell	cycle	exit,	
increased	cell	death,	and	a	reduced	number	of	neurons	[15].		
Interestingly,	 OFC	 suddenly	 increased	 after	 age	 2	 in	 3	 patients	 (Supplementary	 Figure	 1),	 a	
phenomenon	not	 reported	previously	 in	PM.	The	partial	 compensation	observed	could	 result	 from	
postnatal	white	matter	 development,	myelination	 and/or	 synaptogenesis	 [34,	 35].	 Brain	MRI	 early	
follow-up,	including	T2	weighted	images	and	tractography	should	therefore	be	envisioned	to	assess	
myelination	and	synaptogenesis	in	CDK5RAP2	patients.	Despite	the	reduction	in	neuron	number,	it	is	
possible	 that	 neurons	 that	 have	 reached	maturity	manage	 developing	 a	 fairly	 efficient	 network,	 a	
situation	that	would	be	consistent	with	the	mild	ID	observed,	unlike	ASPM	patients	who	have	more	
pronounced	ID	[30].	In	agreement	with	this,	patients	whose	OFC	increases	after	age	2	also	showed	a	
higher	IQ.	Larger	cohorts	would	greatly	help	validating	this	hypothesis.	
IHA	was	 detected	 in	 5	 patients	 and	may	 be	 similar	 to	 a	 forme	 fruste	 of	 holoprosencephaly	 (HPE),	
which	is	restricted	to	the	ventral	part	of	the	diencephalon	and	characterized	by	the	non-separation	
of	hypothalamic	nuclei	along	the	midline	without	fusion	of	the	thalami.	IHA	is	often	associated	with	
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other	CNS	midline	defects	including	corpus	callosum	dysgenesis,	as	seen	in	patients	6	and	7,	or	other	
defects	not	observed	 in	our	patients	 such	as	an	absence	of	 the	 septum	pellucidum,	optic	pathway	
hypoplasia,	 hippocampal	 dysgenesis	 [36,	 37].	 However,	 IHA	 may	 also	 occur	 as	 an	 isolated	
asymptomatic	 feature	 [36].	At	 their	 last	examination,	 the	children	of	our	series	did	not	exhibit	any	
obvious	endocrine	disorder	attributable	to	the	hypothalamic	defect:	growth	was	within	the	normal	
range	 for	weight	and	height;	no	diabetes	 insipidus	or	high	blood	pressure	was	noted.	Although	no	
micropenis	was	detected,	 tracking	puberty	onset	would	be	relevant.	 Interestingly,	patients	1	and	4	
showed	 excessive	 weight	 gain	 (after	 age	 8	 and	 9,	 respectively).	 During	 the	 2nd	 decade	 of	 life,	 we	
propose	to	assess	energy	metabolism	in	these	patients.			
PM	and	HPE	have	already	been	associated	in	patients	carrying	variants	in	the	MCPH7	gene	STIL	[41].	
These	 patients	 exhibit	 a	 mild	 lobar	 form	 of	 HPE	 and	 PM	 with	 gyral	 simplification	 and	
interhemispheric	cysts.	This	 suggests	 that,	as	 for	STIL,	CDK5RAP2	 can	be	added	to	 the	 list	of	genes	
causing	a	forme	fruste	of	HPE	in	humans.		
	
CDK5RAP2	and	ear	development	
We	show	here	 that	CDK5RAP2	 loss	of	 function	also	affects	 the	development	of	 the	 spiral	organ	of	
Corti.	Malformations	of	the	inner	ear	are	found	in	30-40%	of	children	with	sensorineural	hearing	loss	
(SNHL)	 on	 imaging	 (CT,	MRI)	 [43–46].	 Incomplete	 partition	 of	 the	 cochlea	 type	 II	 [33]	 refers	 to	 a	
cochlea	that	has	a	normal	basal	turn	but	a	cystic	apex	with	hypoplasia	of	the	modiolus	and	absence	
of	 the	 interscalar	 septum.	 This	malformation	was	 obvious	 in	 all	 examined	 patients.	 Patient	 2	 also	
showed	 a	 dilated	 vestibule	 and	 vestibular	 aqueduct	 enlargement	 (Mondini	 dysplasia).	 Incomplete	
partition	 of	 the	 cochlea	 type	 II	 is	 a	 congenital	 cause	 of	 sensorineural	 hearing	 loss.	 This	 cochlear	
malformation	typically	occurs	during	WG7	[47].	Hearing	 loss	may	be	mild	to	profound	and	must	be	
evaluated	with	 systematic	 audiometry.	 As	CDK5RAP2	 variants	 described	 in	 the	 present	 study	 have	
not	been	reported	previously,	one	cannot	rule	out	the	possibility	 that	 the	associated	neurosensory	
impairments	 are	 variant-specific.	 However,	 hearing	 loss	 have	 been	 occasionally	 mentioned	 in	
previous	CDK5RAP2	patients	carrying	other	variants	[19,	26]	and	our	systematic	study	suggests	that	
the	 neurosensory	 defects	 are	 constitutive	 of	 the	 CDK5RAP2	 phenotype	 and	 may	 have	 been	
overlooked	previously.	
	
The	 most	 common	 etiology	 of	 Mondini	 dysplasia	 is	 a	 variation	 in	 the	 SLC26A4	 gene	 involved	 in	
Pendred	 syndrome	 [48]	 and	 in	 a	 non-syndromic	 hearing	 loss	 [49],	 but	 variants	 in	 more	 than	 100	
genes	 cause	 severe	 congenital	 or	 progressive	 hearing	 loss	 [50].	 Genes	 involved	 in	 genetic	 SNHL	
encode	proteins	playing	a	role	in	gene	regulation,	fluid	homeostasis,	synaptic	transmission	and	hair	
cell	and	neuronal	maturation,	but	also	 in	stereocilia	 function	[50].	To	date,	no	 interaction	between	
such	proteins	and	CDK5RAP2	has	been	reported.	 In	humans,	the	cochlea	develops	between	WG6-7	
and	10-12,	and	the	vestibule	between	WG9	and	13	[51],	i.e.	at	the	beginning	of	neurogenesis.	It	has	
been	shown	that	 the	brain	volume	reduction	 related	 to	Cdk5rap2-deficient	mice	 is	due	 to	 reduced	
neural	 progenitor	 proliferation,	 cell	 death	 and	 early	 neuronal	 differentiation	 during	 neurogenesis	
[15].	 It	 is	thus	possible	that	the	observed	simplification	of	the	cochlear	spiral	also	reflects	defective	
proliferation	 or	 cell	 death	 leading	 to	 a	 depletion	 of	 the	 pool	 of	 progenitors	 and	 the	 early	
differentiation	 of	 the	 cochlear	 epithelium.	 Given	 that	 hearing	 loss	 was	 not	 congenital	 and	 was	
identified	when	the	youngest	patient	was	6	years	old,	we	recommend	that	audiograms	be	performed	
systematically	 at	 the	 time	 of	 diagnosis,	 and	 possibly,	 repeated	 on	 a	 yearly	 basis.	 Neurosensory	
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management	 of	 these	 patients	 is	 crucial	 as	 it	 considerably	 impacts	 communication,	 learning	 and	
integration	abilities.		
	
CDK5RAP2	and	eye	development	
PM	is	not	commonly	associated	with	microphthalmia	except	in	specific	syndromes	such	as	Warburg-
Micro	syndrome	(#600118,	RAB3GAP1,	#614225,	RAB3GAP2,		#614222,	RAB18,	#615623,	TBC1D20),	
microcephaly	and	chorioretinopathy	type	3	(#616335,	TUBGCP4,	[52])	or	type	6	(#251270,	TUBGCP6,	
[53])	 or	 microcephaly	 with	 or	 without	 chorioretinopathy,	 lymphedema	 and	 mental	 retardation	
(#152950,	KIF11,[54]).	In	the	present	study,	we	have	shown	that	microphthalmia	is	a	cardinal	feature	
of	 the	 CDK5RAP2-associated	 phenotype.	 More	 surprising	 were	 the	 retinal	 pigmentation	 changes	
found	 in	 all	 the	 patients.	 Retinal	 hyperpigmentation	 could	 be	 related	 to	 skin	 hyperpigmentation	
spots	and	is	probably	developmental	due	to	migration	defects	in	melanocytes.	Hypopigmented	spots	
that	 are	 hyper-autofluorescent	 are	 reminiscent	 of	 lipofuscin	 deposits/accumulation	 in	 the	 Retinal	
Pigmentary	Epithelium	(RPE).	No	functional	consequences	on	visual	acuity	or	ERG	were	noticed.	OCT	
was	normal	for	both	patients	tested,	suggesting	that	lipofuscin	accumulation	does	not	alter	the	RPE-
photoreceptor	layer.	Our	patients	still	being	children,	their	ophthalmological	status	obviously	needs	
to	be	reassessed	to	check	whether	lipofuscin	deposits	are	stable	or	increase	with	time	and/or	impact	
visual	 function.	 These	 retinal	 pigmentation	 changes	 do	 not	 resemble	 the	 well-characterized	
chorioretinopathies	associated	with	microcephaly	such	as	those	caused	by	PLK4,	TUBGCP6	(#251270,	
[53]),	TUBGC4	 (#616335,	 [52]),	or	KIF11	 (#152950,	 [54])	variants.	We	propose	 that	 this	new	entity,	
which	resembles	that	described	by	Abdel-Saam	et	al.	prior	to	gene	identification	[55],	may	be	related	
to	CDK5RAP2	variants,	because	it	is	present	in	all	patients	of	the	present	series.	
	
CONCLUSION	
Overall,	 our	 findings	 extend	 the	 phenotype	 associated	 with	 CDK5RAP2	microcephaly	 and	 indicate	
that	MCPH3	 is	 distinct	 from	other	MCPH	by	 its	 association	with	neurosensory	 impairments.	 These	
results	shed	new	light	on	the	role	of	CDK5RAP2	in	brain,	ear	and	eye	development	and	maturation.		
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LEGENDS	of	FIGURES	
Figure	1:	Novel	and	previously	described	CDK5RAP2	variants.	
A:	 Pedigree	 of	 seven	 individuals	 from	 European	 (families	 2,	 4	 and	 5)	 or	 North	 of	 Africa’s	 families	
(families	1	and	3)		
B:	Scheme	representing	novel	variants	in	our	series	and	the	known	variants	in	the	human	CDK5RAP2	
gene	and	corresponding	domain	of	 the	protein.	The	variants	 reported	previously	are	 shown	above	
the	horizontal	line;	novel	variants	from	the	present	study	are	indicated	below	this	line	and	just	above	
the	 exons.	 Various	 symbols	 represent	 missense,	 nonsense,	 splice,	 and	 frameshift	 variants	 as	
indicated.	 Abbreviations:	 γTurc	 (gamma-tubulin	 ring	 complex);	 CM1	 (centrosomin	 (cnn)	 motif	 1);	
SMC	(structural	maintenance	of	chromosomes	protein).	
Figure	2:	Developmental	hypothalamic	defects	in	patients	with	CDK5RAP2	variants.	
Coronal	(A,	C)	and	Sagittal	(B,	D)	T1-weight	images	showing	in	patients	1,	2,	4,	5	and	7	a	structure	iso-
intense	 to	 grey	 matter	 consistent	 with	 an	 inter-hypothalamic	 adhesion	 (IHA,	 white	 arrows),	 and	
absent	in	the	healthy	control.	This	grey	matter	band	on	coronal	view	and	nodular	on	sagittal	view	is	
located	 at	 the	 level	 of	 the	 upper	 midbrain,	 closed	 to	 the	 anterior/inferior	 third	 ventricle.	 IHA	 is	
known	 to	 connect	 both	 dorso-medial	 and	 ventromedial	 hypothalamic	 nuclei	 and/or	 arcuate,	 para-
ventricular	or	pre-optic	nuclei	on	both	sides	of	the	third	ventricle.		
Figure	3:	Retinal	pigmentary	changes	in	patients	with	CDK5RAP2	variants.	
A-B:	 Ocular	 fundus	 photography	 of	 patients	 1	 and	 4	 showing	 focal	 regions	 of	 hyper-	 and	
hypopigmentation	 in	 the	 retinal	 pigment	 epithelium	 (RPE).	 Note	 that	 hyper-pigmented	 lesions	
appeared	as	small	dark	spots	(patient	1,	white	arrows)	or	dark	grey	extended	lesions	(patient	4,	black	
arrow)	and	were	 located	 in	 the	macular	zone	and/or	 in	 the	retinal	periphery.	Small	 round	spots	of	
hypopigmentation	were	scattered	in	the	posterior	pole	(yellow	arrows	in	patients	1	and	4).		
C-D:	Ocular	 fundus	autofluorescence	showing	 that	hyper-pigmented	 lesions	appear	as	well-defined	
patches	of	hypo-auto-fluorescence	(Figure	3C-D,	white	and	black	arrows),	whereas	hypo-pigmented	
spots	appear	as	areas	of	hyper-fluorescence,	reminiscent	of	lipofuscin	deposits/accumulation	in	the	
RPE	in	both	patients	(yellow	arrows).		
Figure	 4:	 Congenital	 inner	 ear	malformation	 responsible	 for	 progressive	 deafness	 in	 patients	 with	
CDK5RAP2	variants.		
A:	Temporal	bone	coronal	CT	scan	images	in	patient	1	and	5	showing	small	cochlea	with	no	visibility	
of	the	interscalar	septa	at	the	apical	turn	of	the	cochlea	and	a	confluence	of	middle	and	apical	turns	
of	the	cochlea,	evocative	of	an	incomplete	partition	type	II	according	to	Sennaroglu	classification.		
B-C:	 Tonal	 and	 vocal	 audiograms	 of	 patients	 1	 (B)	 and	 5	 (C).	 Circles	 and	 X	 symbolize	 joint	 air	 and	
bone-conducted	hearing	thresholds	respectively	for	right	and	left	ears.	
B:			On	the	right	ear,	the	ascending	curve	corresponds	to	a	severe	hearing	loss	whereas	the	left	ear	
demonstrates	a	normal	hearing	threshold	for	conversational	frequencies	associated	with	a	scotoma	
at	6000	Hz.		
C:	The	mean	hearing	threshold	of	80dB	on	the	right	ear	and	70dB	on	the	left	ear	indicate	a	bilateral	
hearing	loss.	
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D-E:	Horizontal	section	of	temporal	bone	(D)	of	a	control	fetus	at	WG12	stained	by	Hematoxylin	and	
Eosin	and	high	magnification	on	the	cochlea	(E)	highlighting	the	structure	of	a	normal	fetal	cochlea.	
RM	=	Reissler’s	membrane,	OC	=	Organ	of	Corti,	SV	=	Stria	vascularis.	Scale	bars:	25	mm	(D),	500µm	
(E).	
F-G:	 Immuno-histochemistry	 in	 the	 adjacent	 section	 of	 the	 cochlea	 of	 the	 control	 fetus	 at	WG12	
shown	 in	D;	 RM	=	 Reissler’s	membrane,	OC	 =	Organ	 of	 Corti,	 SV	 =	 Stria	 vascularis.	White	 squares	
indicate	regions	of	the	cochlea	that	are	shown	in	higher	magnification	in	the	right	part	of	the	panel.	
F:	 Co-labeling	 of	 CDK5RAP2	 (red)	 and	 MYOSIN	 VI	 (green,	 that	 stains	 the	 outer	 hair	 cells	 of	 the	
cochlea)	 and	 DAPI	 (blue)	 showing	 that	 CDK5RAP2	 is	 expressed	 in	MYOSIN	 VI	 positive	 cells	 at	 the	
apical	pole	of	outer	hair	cells.	G:	Co-labeling	of	CDK5RAP2	(red)	and	GAMMA	TUBULIN	(green,	that	
stains	 the	 pericentriolar	material	 at	 the	 centrosome)	 demonstrating	 that	 CDK5RAP2	 is	 localized	 at	
the	 centrosome	 of	 the	 outer	 hair	 cells	 of	 the	 cochlea.	 Scale	 bars:	 90µm	 (first	 left	 panel),	 15µm	
(second	left	panel),	15µm	(right	panel)	
Supplementary	Figure	1:	Clinical	characteristics	of	patients	with	CDK5RAP2	variants.		
A. Morphological	 features	 of	 patients	with	CDK5RAP2	 variants.	No	 dysmorphic	 feature	 has	 been	
noticed	except	a	retrognatism	in	all	patients	and	a	sloping	forehead	in	patients	4	and	5.		
B. OFC	 curve	 of	 patients	 with	 CDK5RAP2	 variants.	 Microcephaly	 was	 obvious	 at	 birth	 for	 all	
patients.	Head	 circumference	at	 last	 examination	 ranged	 from	 -3	 SD	 to	 -7.2	 SD	 (mean	 -6	 SD).	OFC	
curve	slowed	down	with	age	with	an	 increase	of	 the	z-score	 for	all	patients	prior	age	2,	whereas	a	
noteworthy	and	unusual	ascent	of	OFC	after	age	2	was	noticed	in	patients	1,	2	and	4.	
Supplementary	Figure	2:	Neuroimaging	characteristics	of	patients	with	CDK5RAP2	variants.	
Axial	 (A),	Sagital	 (B)	and	coronal	 (C)	T1-weight	 images	showing	the	typical	MRI	 features	of	patients	
with	 CDK5RAP2	 variants,	 with	 a	 reduced	 fronto-occipital	 diameter	 (FOD)	 largely	 under	 the	 3rd	
percentile	for	age	(see	also	Table	2).		Gyration	appeared	simplified	as	the	number	of	second	and/or	
third	 gyri	 were	 reduced	 and	 the	 sulci	 were	 shallow.	 Note	 that	 Patient	 6	 and	 7	 had	 a	 posterior	
agenesis	of	the	CC.	The	CC	was	short	for	the	other	patients	if	only	referring	to	the	measurement	of	
the	 antero-posterior	 diameter	 of	 the	 CC	 (APD).	 Nevertheless,	when	 it	 is	 reported	 to	 the	 FOD,	 the	
APD/FOD	ratio	was	within	the	normal	range	(see	Table	2),	suggesting	that	the	CC	is	not	short	taking	
the	FOD	into	account.	No	abnormal	signal	within	the	periventricular	or	the	subcortical	white	matter	
on	T2-weight	images	was	detected	(D).	
Supplementary	Figure	3:	Cognitive	abilities	of	patients	with	CDK5RAP2	variants.	
Cognitive	profile	of	patients	carrying	CDK5RAP2	variants	according	to	Wechsler	scales.		
Six	patients	out	of	 seven	were	able	 to	perform	all	 the	subtests	of	Wechsler	 scales	 (WISC	 IV,	n	=	6:	
patients	1,	4,	5,	6	and	7,	WPPSI	 III,	n	=	2:	patients	2	and	3).	Patients	3	and	6	couldn’t	be	assessed	
totally,	especially	regarding	Verbal	Comprehension	Index	(VCI)	and	(POI)	because	she	did	not	speak	
our	language.		
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According	 to	 the	 10th	 Revision	 of	 the	 Internal	 Classification	 of	 Disease	 (ICD-10)	 and	 to	 the	 fourth	
revision	 of	 the	 American	 Psychiatric	 Association's	 Diagnostic	 and	 Statistical	 Manual	 (DSM-IV)	
classification,	 five	 patients	 obtained	 a	 full	 scale	 intellectual	 quotient	 (FSIQ)	 within	 the	 mild	
intellectual	disability	(ID)	zone	(50	<	FSIQ	<	70,	light	blue	rectangle)	and	one	patient	had	a	FSIQ	in	the	
moderate	ID	zone	(FSIQ	=	40,	dark	blue	rectangle;	see	also	Table	1).	For	the	latter,	we	cannot	exclude	
a	 second	 hit	 responsible	 for	 lower	 scores.	 Sores	 were	 homogeneous	 whatever	 the	 domain	 under	
evaluation	without	any	significant	differences	between	scales	(one	way	ANOVA,	n	=	7,	ns).	Except	for	
patient	5,	all	patients	obtained	a	score	in	the	lower	range	or	in	the	mild	ID	zone	for	VCI	(57	<	VCI	<	
78,	n=4),	POI	(52	<	POI	<	79,	n=	7)	and	PSI	 (50	<	PSI	<	78,	n=	5).	WMI	scale	was	the	most	dropped	
index	among	school-aged	patients	(50	<	WMI	<	60,	n	=	4),	without	significant	differences	with	other	
scales	(one	way	ANOVA,	n	=	7,	ns).		
	
Supplementary	Figure	4:	The	CDK5RAP2	protein	is	expressed	and	located	at	the	centrosome	of	the	
apical	radial	glial	cells	in	the	VZ	at	early	and	mild	neurogenesis	
WG8	(A-C)	and	WG12	(D-F)	sections	from	control	cortices	stained	for	GAMMA	TUBULIN	(green)	and	
CDK5RAP2	(red)	and	DAPI	(blue);	inserts	show	high	magnification	of	A	in	the	lower	panels	(B-C	and	E-
F)	and	showed	that	CDK5RAP2	co-localized	with	GAMMA	TUBULIN	at	the	centrosome	of	both	mitotic	
apical	 radial	 glial	 cells	 (aRGc)	 and	 non-dividing	 (aRGc)	 in	 the	 VZ	 at	 early	 (WG8)	 and	mild	 (WG12)	
neurogenesis.	 CDK5RAP2	 was	 also	 expressed	 within	 the	 nucleus	 of	 (aRGc),	 although	 to	 a	 lesser	
extent.	VZ:	ventricular	zone,	SVZ:	sub	ventricular	zone.	Scale	bars:	90	µm	(A,	D),	5µm	(B,	C,	F),	10µm	
(E).	
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PATIENTS REFERENCE FAMILY ORIGIN CONSAGUINITY
AGE AT 
DIAGNOSIS 
(years)
Mutation 1 Mutation 2
PRENATAL 
FEATURES
SEX
OFC AT BIRTH 
(SD)
WEIGHT AT 
BIRTH (SD)
HEIGHT AT BIRTH (SD)
AGE AT TIME OF 
EXAMINATION 
(years)
OFC AT 
TIME OF 
EXAMINATI
ON (DS)
WEIGHT AT 
TIME OF 
EXAMINATIO
N (DS)
HEIGHT AT 
TIME OF 
EXAMINATIO
N (DS)
BRAIN IMAGING NEUROLODEVELOPMENTAL OUTCOME EPILEPSY OTHER SYMPTOMS
Patient #1 
Moynihan, 2000/ 
Bond, 2005
#1 Pakistan Yes Not Provided c.246T>A (p.Ser82*) c.246T>A (p.Ser82*) Not Provided M Not Provided Not Provided Not Provided Not Provided -6 Not Provided Not Provided Not performed Mild intellectual disability No No
Patient #2
Moynihan, 2000/ 
Bond, 2005
#1 Pakistan Yes Not Provided c.246T>A (p.Ser82*) c.246T>A (p.Ser82*) Not Provided F Not Provided Not Provided Not Provided Not Provided -8 0,0 0,0 Not performed Moderate intellectual disability
Yes - rare 
tonic/clonic 
seizures
Profound congenital neurosensory deafness
Patient #3
Moynihan, 2000/ 
Bond, 2005
#1 Pakistan Yes Not Provided c.246T>A (p.Ser82*) c.246T>A (p.Ser82*) Not Provided F Not Provided Not Provided Not Provided Not Provided
Not 
Provided
Not Provided Not Provided Not performed IQ 86 No No
Patient #4
Heney, 
1992/Moynihan, 
2000/ Bond, 
2005
#1 Pakistan Yes Not Provided c.246T>A (p.Ser82*) c.246T>A (p.Ser82*) Not Provided F Not Provided Not Provided Not Provided Not Provided
Not 
Provided
Not Provided Not Provided Not performed IQ 89 No
Acute Lymphoblastic Leukemia causing death - skin 
areas of hypopigmentation
Patient #5 Bond, 2005 #2 Pakistan Yes Not Provided c.4005-15A>G (p.E386fs*4) c.4005-15A>G (p.E386fs*4) Not Provided F Not Provided Not Provided Not Provided Not Provided -5 Not Provided Not Provided Not Provided Moderate intellectual disability Not Provided Not Provided
Patient #6 Bond, 2005 #2 Pakistan Yes Not Provided c.4005-15A>G (p.E386fs*4) c.4005-15A>G (p.E386fs*4) Not Provided F Not Provided Not Provided Not Provided Not Provided -7 Not Provided Not Provided Not Provided Moderate intellectual disability Not Provided Not Provided
Patient #7 Hassan, 2007 #3 Pakistan Yes c.246T>A (p.Ser82*) c.246T>A (p.Ser82*) Not Provided F Not Provided Not Provided Not Provided Not Provided -4 Not Provided Not Provided Not Provided  IQ 51 No No
Patient #8 Hassan, 2007 #3 Pakistan Yes c.246T>A (p.Ser82*) c.246T>A (p.Ser82*) Not Provided F Not Provided Not Provided Not Provided Not Provided -7 Not Provided Not Provided Not Provided IQ 65 No No
Patient #9 Hassan, 2007 #3 Pakistan Yes c.246T>A (p.Ser82*) c.246T>A (p.Ser82*) Not Provided M Not Provided Not Provided Not Provided Not Provided
Not 
Provided
Not Provided Not Provided Not Provided No No
Patient #10 Hassan, 2007 #3 Pakistan Yes c.246T>A (p.Ser82*) c.246T>A (p.Ser82*) Not Provided M Not Provided Not Provided Not Provided Not Provided
Not 
Provided
Not Provided Not Provided Not Provided No No
Patient #11
Pagnamenta, 
2012
#4 Somalia Yes 6 c.700G<T (p.Glu234*) c.700G<T (p.Glu234*) Not Provided F -3.7 -2,4 -3,7 6 -8,9 -1,1 -1,6 No abnormalities Mild intellectual disability No
severe gastric reflux - Moderate to severe bilateral 
neurosensory deafness - Slight  hyperlaxity - Hypotonia
Patient #12 Issa, 2013 #5 Italy Yes Not Provided c.4441C>T (p.Arg1481*) c.4441C>T (p.Arg1481*) Not Provided M Not Provided 0,5 Not Provided 5 -6 Not Provided -4,1
Simplified gyral pattern (mostly frontal) - corpus 
callosum agenesis
IQ 69 No
Abdominal hernia - Skin areas of hyperpigmentation - 
Behavioral disorder - Tic disorder
Patient #13 Issa, 2013 #5 Italy Yes Not Provided c.4441C>T (p.Arg1481*) c.4441C>T (p.Arg1481*) Not Provided M -3,5 -0,5 -0,5 2 -5 Not Provided
Simplified gyral pattern (mostly frontal) - corpus 
callosum and cerebellar hypoplasia
IQ 56 No Skin areas of hyperpigmentation -Behavioral disorders
Patient #14 Lancaster, 2013 #6 Not Provided No Not Provided c.4546G>T (p.Glu1516*) c.4672C>T (p.Arg1558*) Microcephaly -6,5 -3,9 -5 3 -13,2 Not Provided -6,7 Simplified gyral pattern Not Provided No Neurosensory deafness
Patient #15 Tan, 2014 #7 Caucasian No 5
c.524_528del(p.Gln175Argfs*
42)
c.4005-1G>A (fs*) Microcephaly F Not Provided Not Provided Not Provided 6 -8,9 -1,5 -3 No abnormalities IQ 75 No Asthma - Allergies - Sleep apnea
Patient #16 Li, 2015 #8 Hispanic No 0.5 c.4441C>T (p.Arg1481*) c.5227C>T (p.Gln1743*) No M -3,1 -0,3 -1,5 Not Provided
Not 
Provided
Not Provided Not Provided Short corpus callosum Not Provided No Failure to thrive (enteral nutrition)
Patient #17 Yigit, 2015 #9 Turkey Yes Not Provided
c.4005-9A>G 
(p.Arg1335Serfs*3)
c.4005-9A>G 
(p.Arg1335Serfs*3)
No M Not Provided -2 Not Provided 9 -4 Not Provided -3,2 Not Provided Not Provided No Bone age delay -5th finger clinodactyly - 11 pairs of ribs
Patient #18 Yigit, 2015 #9 Turkey Yes Not Provided
c.4005-9A>G 
(p.Arg1335Serfs*3)
c.4005-9A>G 
(p.Arg1335Serfs*3)
Not Provided F Not Provided Not Provided Not Provided 10 -4 Not Provided -3,4 No abnormalities Mild intellectual disability No Congenital hip dislocation
Patient #19 Yigit, 2015 #10 Pakistan Yes Not Provided c.383+1G>C(p.Lys129*) c.383+1G>C(p.Lys129*) Not Provided F Not Provided -2 Not Provided 2 -6,2 Not Provided -5 No abnormalities Not Provided No Not Provided
Patient #20 Jouan, 2016 #11 Canada No 53 c.280G>A (p.Gly94Arg) c.3695A>G (p.Asn1232Ser) No F Not Provided Not Provided Not Provided 53 1,0 Not Provided 0,0 Corpus callosum agenesis IQ 84 No Learning disabilities
Patient #21 Jouan, 2016 #11 Canada No 52 c.280G>A (p.Gly94Arg) c.3695A>G (p.Asn1232Ser) No F Not Provided Not Provided Not Provided 52 -1,3 Not Provided -0,5 Corpus callosum agenesis IQ 78 No Mutism - Intermittent ataxia
Patient #22 Jouan, 2016 #11 Canada No 44 c.280G>A (p.Gly94Arg) c.3695A>G (p.Asn1232Ser) Not Provided M Not Provided Not Provided Not Provided 44 -1,3 Not Provided 0,5 Corpus callosum agenesis IQ 77 Resolutive obsessive-compulsive disorder
Patient #23
Pagnamenta, 
2016
#12 Not Provided No 11 c.4604+1G>C c.3097delG (p.V1033 fs*41) Not Provided M Not Provided Not Provided Not Provided 11 -5,5 Not Provided Not Provided No abnormalities developmental quotien: 45 No Café-au-lait spots
Patient #24 Abdullah, 2017 #13 Pakistan Yes 30
c.5127_5128dupGT 
(p.Ser1710CysfsTer22)
c.5127_5128dupGT 
(p.Ser1710CysfsTer22)
Not Provided F Not Provided Not Provided Not Provided 30
Not 
Provided
Not Provided Not Provided Severe intellectual disability - walking No
Patient #25 Abdullah, 2017 #13 Pakistan Yes 32
c.5127_5128dupGT 
(p.Ser1710CysfsTer22)
c.5127_5128dupGT 
(p.Ser1710CysfsTer22)
Not Provided M Not Provided Not Provided Not Provided 32
Not 
Provided
Not Provided Not Provided Severe intellectual disability - walking No Moderate hearing impairment
Patient #26 Abdullah, 2017 #13 Pakistan Yes 12
c.5127_5128dupGT 
(p.Ser1710CysfsTer22)
c.5127_5128dupGT 
(p.Ser1710CysfsTer22)
Not Provided M Not Provided Not Provided Not Provided 12
Not 
Provided
Not Provided Not Provided Moderate intellectual disability No
Patient #27 Abdullah, 2017 #13 Pakistan Yes 8
c.5127_5128dupGT 
(p.Ser1710CysfsTer22)
c.5127_5128dupGT 
(p.Ser1710CysfsTer22)
Not Provided F Not Provided Not Provided Not Provided 8
Not 
Provided
Not Provided Not Provided Moderate intellectual disability No
Patient #28 Ahmad, 2017 #14 Pakistan Yes Not Provided c.1279C>T (p.Arg427*) c.1279C>T (p.Arg427*) Not Provided NP Not Provided Not Provided Not Provided Not Provided
Not 
Provided
Not Provided Not Provided Not Provided Not Provided Not Provided Not Provided
Patient #29
Sukumaran, 
2017
#15 Pakistan Yes 16 c.4114C > T (p.Arg1372*) c.4114C > T (p.Arg1372*) Not Provided F Not Provided Not Provided Not Provided 16 -5 Not Provided Not Provided Mild intellectual disability No
Patient #30
Sukumaran, 
2017
#15 Pakistan Yes 12 c.4114C > T (p.Arg1372*) c.4114C > T (p.Arg1372*) Not Provided M Not Provided Not Provided Not Provided 12 -9 Not Provided Not Provided Mild intellectual disability No
Patient #31 Alfares, 2018 #16 Saudi Arabia Yes 16 c.4055A>G (p.Glu1352Gly) c.4055A>G (p.Glu1352Gly) Not Provided M -2 1100 Not Provided Not Provided
Not 
Provided
Not Provided Not Provided White matter abnormalities
Severe intellectual disability - non 
walking
Yes - epileptic 
encephalopathy 
with 
hypsarrhythmia
Bilateral cataract - White matter abnormalities - 
Tetrapyramidal syndrome
Patient #32 Alfares, 2018 #16 Saudi Arabia Yes 10 c.4055A>G (p.Glu1352Gly) c.4055A>G (p.Glu1352Gly) Not Provided M Not Provided Not Provided Not Provided 10 -2 -4 -4 moderate ventriculomegaly
Severe intellectual disability - non 
walking
Yes Bilateral cataract - Tetrapyramidal syndrome - Dystonia
Patient #33 Alfares, 2018 #16 Saudi Arabia Yes 8 c.4055A>G (p.Glu1352Gly) c.4055A>G (p.Glu1352Gly) Not Provided F Not Provided Not Provided Not Provided 8 -4 -4,5 -5 Thin corpus callosum
Severe intellectual disability - non 
walking
Yes - epileptic 
encephalopathy 
with 
hypsarrhythmia
Bilateral cataract - Tetrapyramidal syndrome
Patient #34 Alfares, 2018 #16 Saudi Arabia Yes 6 c.4055A>G (p.Glu1352Gly) c.4055A>G (p.Glu1352Gly)
Intra uterine 
growth 
retardation
M -2 1700 Not Provided 0,75 -4 Not Provided Not Provided Thin corpus callosum Not Provided Yes
Bilateral cataract - Hypospadias - Bilateral 
cryptorchidism - Cardiac congenital defect
Patient #35 Alfares, 2018 #17 Saudi Arabia Not Provided 3 c.4672C>T p.(Arg1558*) c.4672C>T p.(Arg1558*) Not Provided M -3,5 Not Provided Not Provided Not Provided
Not 
Provided
Not Provided Not Provided Decreased cerebral volume Intellectual disability Yes Cataract
18-30 
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